WHO ICTRP trial
The New Zealand Indigo naturalis dose-escalation study (NZ-INDES): a study to…
ACTRN12621000097842 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12621000097842 |
|---|---|
| Public title | The New Zealand Indigo naturalis dose-escalation study (NZ-INDES): a study to investigate its effect on immune responses in healthy volunteers |
| Scientific title | Impact of a single intake of Indigo naturalis on the activity of blood aryl hydrocarbon receptor in healthy individuals |
| Primary sponsor | Malaghan Institute of Medical Research |
| Secondary sponsors | Capital & Coast District Health Board (CCDHB) |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | New Zealand |
| Conditions | Inflammation; Inflammation;Inflammatory and Immune System - Normal development and function of the immune system;Alternative and Complementary Medicine - Herbal remedies |
| Interventions | Study design: This is a single dose, open-label, dose-escalation pilot study. Following a lead-in period for screening, recruitment, participants will be allocated either to a zero-dose control group, or, only one of the four different… |
| Registration date | Jan 2, 2021 |
| Target size | 25 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: